Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07558343
NA

Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2

Sponsor: Institut Claudius Regaud

View on ClinicalTrials.gov

Summary

This is an interventional, prospective, single-center study designed to collect and describe genetic, environmental and psychosocial control data from male participants. The participants did not have any prior history of cancer at the time of the oncogenetic consultation and do not have the family mutation researched during the oncogenetic consultation (targeted genetic testing). The participants are referenced in the IUCT-O medical records as family members of patients suffering from male breast cancer. The study will be conducted on a population of 120 participants.

Key Details

Gender

MALE

Age Range

66 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2026-10-15

Completion Date

2027-10-15

Last Updated

2026-08-19

Healthy Volunteers

No

Interventions

OTHER

Questionnaire completion

In order to meet the study's objective, after written informed consent was obtained, participants will be asked to complete a questionnaire characterizing their environmental and psychosocial context. The questionnaire is to be filled out by the participants at home. It is estimated that the questionnaire will take around 30 minutes to complete. Demographics data will also be collected from the medical records of included participants.

OTHER

Genetic analysis (WES)

In order to meet the study's objective, after completion of the questionnaire, a genetic analysis (Whole Exome Sequencing) will be conducted on an archived blood sample collected during the initial oncogenetics consultation. The patient had given consent to this sample in order for the oncogenetics laboratory to perform the targeted genetic analysis (presence of family mutation). No additional blood sample will be collected for the purpose of this study.

Locations (1)

Institut Universitaire du Cancer Toulouse - Oncopole, Laboratoire d'oncogénétique

Toulouse, France